continu ach
view sector perform-r report impress
beat rais already-elev expect follow
posit pre-announce howev upsid result excit
investor cepheid outsiz core revenu growth power
sever flu season growth repeat year
though dental stumbl organ declin manag
cautious optimist bottom could sight
solid beat rais upsid diagnost cepheid
even expect rais higher follow posit
pre-announce still manag beat consensu
cash ep estim sizeabl driven mostli upsid
diagnost expect strength mostli attribut cepheid
achiev organ growth fuel sever flu season
year neg surpris quarter organ
declin chronically-challeng dental segment due on-going
distribut channel inventori destock howev manag
cautious optimist trend could bottom flattish dental
organ revenu channel sell-out growth posit
past two quarter regard full-year guidanc rais
cash ep rang midpoint attribut beat
ep upsid remaind year due
improv order margin fx cent deal accret
rais cash ep estim high-
end guidanc price target
beat rais investor may disappoint
guidanc boost higher potenti contribut
stock modest bp under-perform vs peer
take may investor less familiar
outsiz growth cepheid repeat year
implications/read-across dental result expect stabil
remaind despit stumbl organ declin
manag cautious optimist dental stabil flattish
organ revenu north american sell-out trend return
growth recent quarter also note inventori destock
proactiv pull forward quarter
valuat near high-end rel rang trade
premium peer adjust ep cash ep vs target rang
price target assum trade premium
valu usd unless otherwis note
price prior trade day market close estimate unless otherwis note
capit market appreci consider institut investor all-america research survey
bloomberg capit market estim upside/downside/target
follow spin fortiv corp believ
re-rat higher beyond rel price-to-earnings rang within
trade histor target rang
given divest cyclic
legaci industri busi believ trade
near high-end rang due strong
outlook potenti catalyst
premium target group multipl price-to-earnings
adjust ep cash ep impli
valuat support sector perform rate
deliv upsid pall cepheid synergies/
accret market enter risk-off environ
believ stock may abl re-rat beyond
high-end rel rang premium
target group multipl adjust ep
also see potenti upsid adjust ep
level includ acceler organ growth end market
carri execut risk misstep
 integr could weigh stock addit
high-qual defens name would also lag
market enter prolong risk-on environ favor
cyclic higher-beta stock could see price-to-earnings contract
premium peer low-end
target rel rang also chanc end market
slowdown result adjust ep closer
valuat
break-up long advoc
break-up scenario unlock long-term sharehold valu
remov vex law larg number hamper
 growth engin view spin-out
industri busi publicly-trad corp
allow remainco revit growth-by-
acquisit engin carri less-cycl best-in-class
portfolio stronger cash gener
rank among higher qualiti earn compani
higher qualiti prime coverag accord
invest framework fundament remain
impress sector-best consecut year
know-how rever danah busi system
posit includ recur revenu market
leadership across portfolio
acquisit long-covet pall corp ideal strateg
fit valuat pricey last remain public
filtrat pure-play pall like danah wish-list
mani year lead mileston billion
acquisit close pricey
ebitda takeout multipl below-benchmark forecast
spawn new concern among investor danah
compromis disciplin longer term
believ pall huge strateg winner million
target cost synergi priced-for-perfect
valuat add risk integr misstep synergi
shortfal vindic skeptic
balanc sheet fulli reload comfort return
larger deal size keep pipelin
contain million small bolt-on deal
recent disclos becom
comfort return larger multi-billion dollar deal
size vein billion cepheid acquisit
even deploy billion acquisit
estim still anoth billion
firepow could feasibl deploy next
month suggest healthi level balanc sheet capacity/
option deal-mak medium-term
given expens price-tag below-benchmark
expect return major integr stumbl pall
cepheid would damag faith investor
takeaway result
revenu high growth
market roughli
led double-digit
china india
quarter double-digit
meanwhil us
low-single-digit
europ mid-single-
digit quarter
report cash ep outpac posit pre-announce guidanc
already-boost estim report cash ep
nice outpac estim consensu note estim
boost higher posit pre-announce cash
ep track exceed previous commun guidanc rang
howev ep upsid quarter even greater anticip driven entir
oper line total compani organ growth roughli in-lin
estim meanwhil gross margin expand new compani record
oper margin expand bp y/i nice outpac estim
bp increment margin solid segment posit standout quarter
diagnost achiev organ growth bp y/i margin expans
contrast biggest disappoint unexpect organ revenu declin
bp y/i margin contract beleagu dental segment overal
oper line came estim compris life scienc
diagnost dental environment appli solut higher
corpor expens final free cash flow convers quarter especi
strong given typic season weakest cash gener quarter
histor averag convers
exhibit danah earn guidanc vs estim
boost cash ep guidanc rang impress midpoint
expect boost full-year cash ep guidanc move previou rang
impli increas midpoint new
midpoint came slightli prior estim consensu addit
initi organ growth target cash ep guidanc rang
exactli in-lin predict given pace organ growth
expect clear initi full-year guidanc rang
understat longer applic howev manag declin provid
explicit new forecast opt wait visibl trend regard
boost ep guidanc rang roughli attribut upsid
anoth compris stronger order margin foreign exchang tailwind
earlier complet acquisit close last week manag
previous estim deal would close around mid-year produc
ep accret earlier-than-anticip close impli
accret might potenti pull forward sourc earn upsid
partli off-set acceler growth invest across year
rais cash ep estim high-end
guidanc rang upsid attribut ep beat vs estim
along increment deal accret fx tailwind organ revenu
growth forecast full-year sequenti deceler
final rais cash ep estim
high-end guidanc
diagnost danah oper upsid quarter primarili attribut
diagnost segment saw organ revenu increas impress
oper margin expand bp y/i primarili thank organ growth
cepheid due combin good commerci execut test menu expans
high demand molecular test kit combat sever flu season year exclud
tailwind flu-rel demand cepheid organ revenu still-healthi mid-
teen quarter remind sinc cepheid acquir busi
expand gross margin bp oper margin break-even
mid-teen today manag confid cepheid expand lead
market posit gain share molecular diagnost meanwhil beckman coulter
organ revenu low-single-digit y/i led high growth market like china
radiomet grew mid-single-digit leica biosystem deliv high-single-digit
broad-bas strength across major product line
dental biggest disappoint dental organ revenu declin
repres segment worst quarterli perform sinc remind dental
continu suffer inventori destock distribut channel equip
tradit consum roil industri year specif
manag discuss exclus arrang dental market
manufactur like dentspli sirona distributor like patterson henri
schein phase market open relationship redrawn creat
level play field result market midst rightsiz inventori
level channel partner work familiar new
product catalogu incent system dynam top-line headwind dental
expect persist least moder later year
proactiv team distributor help adjust inventori within
channel result revenu shortfal accord manag exclud
inventori reduct dental organ revenu would roughli flat y/i
look ahead manag expect dental organ revenu flattish
cautious optimist busi final found bottom note sell-out
trend north american channel tradit consum achiev second
consecut quarter posit growth impli demand stabil
would make much question potenti exit dental
remind manag treat dental new acquisit past two
year effort turnaround segment includ initi reposit
platform brand consolid gener cost save
ration spur higher organ growth new product invest far
dental success consolid number opco ten three past
two year streamlin
back-office/manufactur footprint
manag believ dental still middl inning turnaround
line-of-sight expand segment margin mid-teen long-term
said earn call ceo tom joyc state board
constantli review whether individu busi belong portfolio longer-
term say compani alway busi perman
home would downplay notion would walk away
busi still valu created/restor
dental revenu mix
equip
life scienc revenu life scienc organ revenu healthi
quarter core oper margin expand bp y/i repres
seventh consecut quarter bp core margin improv beckman life
scienc saw double-digit organ growth posit perform across major product
line region leica microsystem low-single-digit sciex high-
single-digit meanwhil phenomenex achiev double-digit organ growth quarter
regard pall biopharma vertic double-digit industri vertic
achiev second consecut quarter growth driven strong order trend final
complet billion acquisit last week ad market-lead
provid reagents/consum genom applic portfolio effect
unlock brand new billion address market grow double-digit
plan oper stand-alone compani within life scienc segment
growth quarter mid-single-digit product id water qualiti oper
margin contract bp y/i compris bp headwind bp
core expans partli drag upsiz restructur invest within
product id mark code busi achiev broad-bas strength across major
product line geographi packag color solut achiev low-single-digit
organ growth thank north america western europ meanwhil water qualiti
saw mid-single-digit organ growth hach china thank businesss
enhanc commerci execut leverag chines epa activ project pipelin
result busi increas win-rat chines municip project chemtreat
organ revenu low-single-digit growth mine power partli off-set
softer chemic oil ga result final trojan deliv high-single-digit organ growth
thank strong custom win-rat market share gain along solid momentum
north american chines municip market
upcom catalyst point monitor
orderli one-year cfo transit plan underway conjunct earn result
announc current cfo coma begin gradual transit toward
retir pass cfo torch matt mcgrew current group cfo
diagnost dental effect januari big fan mr coma age
capabl held cfo posit year sinc april buy-sid sell-
side poll mr coma perenni top-rank public compani cfo multi-
industri sector help drive four-fold increas market cap
tenur highlight mr comass plan departur age roughli
consist predecessor pat allend left age view one-year
earli notic hallmark well-sign orderli transit plan also note
mr coma continu key role like final known
mr mcgrew age mani year previous vice-president investor relat
serv busi line financ leader work across intern audit
 investor relat group cfo sinc complet
confid matt mcgrew compani next cfo
acquir genom consum provid integr dna technolog roughli
billion april complet acquisit privat held provid
reagents/consum genom applic significantli expand danah
presenc fast-grow genom market compani previous
modestli expos beckman life scienc busi estim
purchas price roughli billion impli rel full ebitda
multipl overal believ valuat reason given prevail
multipl biotech genom stock today term cash ep accret
expect contribut cent idt reagent use
genom applic like molecular biolog qpcr next-gener sequenc synthet
biolog gene edit molecular diagnost primari function
manufactur custom dna rna oligonucleotid view match
key characterist ideal acquisit target includ market-lead
recurring/consum mix attract margin said manag conced
expect acquisit reach double-digit join pall
cepheid grow list larg acquisit fallen short
previous strict return threshold
expect achiev double-digit core revenu growth attract margin
compani averag expect gener million
revenu next month would account total mix
life scienc addit busi achiev mid-teen core revenu
compound-annual-growth-rate past three year manag expect maintain pace
double-digit core growth futur importantli achiev attract gross
margin vs ebitda margin vs
manag plan oper stand-alone busi portfolio
expect achiev meaning synergi leverag life scienc platform
intern scale idt geograph mix us implement db
expand profit time
balanc sheet fulli reload least billion addit capac
estim keep pipelin contain million small bolt-on
deal recent disclos becom comfort
return larger multi-billion dollar deal-siz vein billion cepheid
acquisit even billion acquisit estim compani still
billion firepow feasibl deploy next month net
debt-to-ebitda current suggest healthi level capac
deal-mak medium-term importantli manag note seller
feel good asset valuat recent passag us tax reform elimin
uncertainti linger market primari criteria
double-digit year-thre small bolt-on deal year-fiv larger
acquisit key characterist attract target includ
fragment market secular growth driver high barrier entri compani
strong brand direct busi custom intimaci recur revenu
rel price-to-earnings trade near high-end target rang follow
fortiv spin juli believ achiev multipl expans beyond
histor valuat level given cyclic legaci industri busi
remov portfolio believ target rel premium rang vs
peer applic new portfolio current trade
premium group report ep cash ep believ stock
trade premium target group multipl impli price
target support sector perform rate current level
ev/ebitda premium higher qualiti ev/ebitda basi trade
estim repres rel premium multi-industri peer
group averag surpris premium group given outsiz
 a-driven amort premium price-to-earnings
share price trade premium weight averag price-to-earnings
publicly-trad peer report ep cash ep believ danah
deserv premium reflect market leadership differenti db toolkit
share price assum after-tax cost capit beta annual sale
growth termin growth rate
compani report capit market estim
millionsmarjunsepdecmarjunsepdecmar-ajunsepdecmarjunsepdecseg revenueslif environment appli total revenu organ revenu sale gener incomelif appli expens oper interest expens incom intang per share per share per share earn per share outstand outstand analysi gross oper pre-tax net incom sale sell gener research tax new pension account corpor expens exhibit danah annual incom statement
compani report capit market estim
revenueslif appli revenu sale gener incomelif appli expens oper income/expense- net interest intang per share earn per share per share earn per share outstand outstand analysi gross oper pre-tax net incom sale sell gener research tax asdiscontinu oper electr equip multi-industri
follow spin fortiv corp believ re-rat higher beyond
rel price-to-earnings rang within trade histor target
rang given divest cyclic legaci industri
busi believ trade near high-end rang due healthi
outlook potenti catalyst premium
target group multipl price-to-earnings adjust ep cash ep impli
valuat support sector perform rate
risk rate price target
acquisit one acquisit compani multi-industri sector
alway risk overpay experienc integr difficulti major
deal given pricey pall cepheid acquisit multipl believ integr
stumbl would damag investor trust leadership
organ growth acquisition-focus busi model investor often hone
organ revenu growth metric perceiv miss often
disproportion effect stock earn
econom condit macro trend inflat currenc credit avail suppli
chain materi cost could caus result lower forecast
financi risk disrupt global credit market could caus sale
earn estim optimist
margin sinc gener among highest gross margin sector
degre execut risk would see shortfal profit
regulatori chang govern regul us intern could
neg impact compani especi elev
beneficiari increas regul water product mark
manag success oper histori execut legendari
db framework seen manag talent period poach
industri compani time exodu talent could affect oper
manufactur market profession medic industri commerci
product servic facil locat across countri compani oper
four segment life scienc diagnost dental environment appli solut
also oper differenti framework growth lean leadership tool
process known danah busi system across aspect oper includ
product develop qualiti control global sourc sale market danah
modestli headquart washington employ peopl global
